This trial is testing the safety of a new drug, enobosarm, when used with the existing drug Verzenio. The second part of the trial is testing whether the new drug combination is more effective than just Verzenio alone in treating metastatic breast cancer.
2 Primary · 2 Secondary · Reporting Duration: Day 1 to Day 300
186 Total Participants · 3 Treatment Groups
Primary Treatment: Enobosarm & Abemaciclib Combo · No Placebo Group · Phase 3
Age 18 - 100 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: